ArticleFrontiers in molecular biosciences2025
Untargeted metabolomics reveals the metabolic characteristics and biomarkers of obstetric antiphospholipid syndrome and undifferentiated connective tissue disease.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The clinical differentiation between obstetric antiphospholipid syndrome (OAPS) and undifferentiated connective tissue disease (UCTD) presents significant diagnostic challenges. This study employs metabolomics to investigate metabolic reprogramming patterns in OAPS and UCTD, aiming to identify potential biomarkers for early diagnosis. Methods: Using LC-MS-based metabolomics, we analyzed serum profiles from 40 OAPS patients (B1), 30 OAPS + UCTD patients (B2), 27 UCTD patients (B3), and 30 healthy controls (A1). Multivariate PLS-DA modeling, combined with KEGG pathway and Gene Set Enrichment Analysis (GSEA), was applied to identify disease-specific metabolic signatures. Results: Metabolomic profiling detected 1,227 metabolites, including 412 in negative ion mode and 815 in positive ion mode. The two ionization modes exhibited distinct chemical profiles, with PLS-DA analysis demonstrating superior group discrimination in positive ion mode. B1 vs B2 (Negative ion mode): nine metabolites were upregulated (notably 17(S)-HpDHA, showing the largest fold-change as a potential biomarker), and one metabolite was downregulated (5-sulfosalicylic acid). B1 vs B2 (Positive ion mode): 17 metabolites were upregulated (including 4-methyl-5-thiazoleethanol, a promising biomarker), and eight were downregulated. B1 vs B3 (Negative ion mode): 14 metabolites were upregulated (highlighted by 3-hydroxybenzoic acid, the most significantly altered candidate), and four were downregulated. B1 vs B3 (Positive ion mode): 30 metabolites were upregulated (again featuring 4-methyl-5-thiazoleethanol), and 32 were downregulated. B2 vs B3 (Negative ion mode): 15 metabolites were upregulated (e.g., chlortetracycline), and 15 were downregulated (notably 6α-prostaglandin I1). B2 vs B3 (Positive ion mode): 29 metabolites were upregulated (e.g., senecionine), and 64 were downregulated (e.g., SM 9:1 2O/16:4). These metabolites represent robust candidates for group discrimination. Enrichment analysis revealed that distinct metabolic pathways were significantly associated with different groups and ionization modes, suggesting divergent underlying metabolic mechanisms. Conclusion: This study systematically characterizes the metabolic reprogramming in OAPS, UCTD, and their comorbid states, identifying potential diagnostic biomarkers. Differential metabolites and pathway analyses highlight the critical role of immunity, contributing to a theoretical framework for "metabolism-immunity-vascular" interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.